Proficio Capital Partners LLC Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Proficio Capital Partners LLC acquired a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 24,113 shares of the company’s stock, valued at approximately $163,000.

Other hedge funds also recently made changes to their positions in the company. Decker Retirement Planning Inc. acquired a new position in Recursion Pharmaceuticals in the fourth quarter worth approximately $26,000. Private Trust Co. NA acquired a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth $27,000. GAMMA Investing LLC raised its position in shares of Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the period. Colonial River Investments LLC purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at $68,000. Finally, Centaurus Financial Inc. acquired a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at $71,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $5.97 on Friday. The company has a market capitalization of $2.40 billion, a PE ratio of -3.90 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company’s 50 day moving average price is $7.46 and its 200 day moving average price is $7.00. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.60 and a 52 week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same period last year, the company posted ($0.42) earnings per share. The company’s revenue was down 57.8% compared to the same quarter last year. Research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on RXRX. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. KeyCorp cut their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Finally, Leerink Partners cut their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $8.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.